Endocrine Abstracts

GLP-1 receptor agonists are commonly used in Type 2 Diabetes and obesity but are less frequently prescribed in Type 1 Diabetes (T1D). In selected T1D patients with elevated BMI, they may aid in glycaemic control and weight reduction. A retrospective analysis was conducted on 97 T1D patients from three diabetes clinics in Dublin. Data on HbA1c, weight, BMI, and CGM metrics were collected pre- and post-GLP-1 initiation. Statistical analyses included Wilcoxon Signed Ranks, Mann-Whitney, and Kruskal-Wallis tests, given a non-normal distribution. Median age was 53 years; 63.9% were female. Semaglutide was the most prescribed agent (63.9%). Median HbA1c improved from 63 to 57.5 mmol/l/mol (7.9% to 7.4%) (r = 0.24, P < .001). No significant differences were found by gender, age, or GLP-1 type. Among patients with baseline HbA1c ≥65 mmol/l/mol, 52.3% achieved a ≥10% reduction. Weight decreased from 94.75 to 90.65 kg and BMI from 31.8 to 31.6 (r = 0.17, P < .05). A ≥5% weight loss was observed in 30% of participants, most commonly in those with BMI ≥35. No significant changes were found in TIR, GMI, or total daily insulin dose. No statistically significant difference was observed in the percentage change of HbA1c across patient BMI categories. GLP-1 receptor agonists were associated with modest improvements in HbA1c and weight among patients with T1D, particularly in those with poor baseline glycaemic control or higher BMIs. Their use may provide an effective adjunctive strategy in selected T1D populations.